# NTLA — slm-full-cpu

## Metadata

ticker: NTLA
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 99f0eba8dbf15c1dad21743681b6b3c7c2114fcee690eb4da8a02ce887bcd302
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 632, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 165.617, "latency_s_total": 165.617, "parse_failure": 0, "prompt_tokens": 3136, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 460, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 147.013, "latency_s_total": 147.013, "parse_failure": 0, "prompt_tokens": 3035, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 153, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 44.493, "latency_s_total": 44.493, "parse_failure": 0, "prompt_tokens": 673, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 133, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 35.046, "latency_s_total": 35.046, "parse_failure": 0, "prompt_tokens": 667, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 163, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 45.749, "latency_s_total": 45.749, "parse_failure": 0, "prompt_tokens": 535, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 164, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 59.917, "latency_s_total": 59.917, "parse_failure": 0, "prompt_tokens": 715, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 923, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 140.447, "latency_s_total": 140.447, "parse_failure": 0, "prompt_tokens": 1610, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NTLA",
  "company_name": "Intellia Therapeutics, Inc.",
  "current_price": 12.75,
  "currency": "USD",
  "market_cap": 1786615296.0,
  "forward_pe": -4.9056764,
  "week_52_high": 28.25,
  "week_52_low": 7.95,
  "financial_currency": "USD",
  "revenue": 59506000.0,
  "net_income": -399975008.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-26",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any factor or combination of factors may "
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-06",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any f"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for the year ended December 31, 2025, the key takeaways regarding risk factors for NTLA include:

**1. Unproven Technology and Development Risks**
*   CRISPR genome editing technology, particularly *in vivo* applications, is relatively new and its therapeutic utility is largely unproven.
*   The company’s approaches to discovering and developing novel therapeutics are unproven and may never result in marketable products.
*   Success requires solving complex issues, such as safely delivering therapeutic agents to target cells, optimizing efficacy and specificity, and demonstrating safety, potency, and purity. There is no assurance these issues will be resolved.

**2. Regulatory and Approval Uncertainties**
*   While one CRISPR-edited *ex vivo* therapy has been approved in the U.S. and EU, no genome editing *in vivo* therapy has been approved in these or other key jurisdictions.
*   Regulatory agencies (such as the FDA, MHRA, and EMA) have limited experience with the clinical development of CRISPR-based therapeutics, particularly *in vivo* ones, which may lead to additional testing requirements or delays.
*   The company is in clinical-stage development for nexiguran ziclumeran (NTLA-2001, pending resolution of a clinical hold on the MAGNITUDE trial) and lonvoguran ziclumeran (NTLA-2002), with other candidates advancing toward clinical testing.

**3. Commercialization and Adoption Challenges**
*   Public perception, media coverage, and ethical concerns regarding genome editing may negatively impact subject participation in clinical trials and physician/patient acceptance of treatments.
*   Physicians, healthcare providers, and payors are often slow to adopt new technologies, particularly those requiring additional upfront costs and training. Physicians may deem the therapies too complex or risky to adopt.
*   Certain patients may not be candidates for therapies due to health conditions or genetic profiles.

**4. Clinical Trial and Operational Risks**
*   The company faces numerous potential delays or failures in clinical trials, including challenges in obtaining regulatory authorization, reaching agreement with trial sites or CROs, and achieving sufficient enrollment rates.
*   Trials may fail to show safety or efficacy, produce negative results, or be suspended/terminated due to safety concerns or noncompliance.
*   Manufacturing and supply chain risks include the potential for insufficient or inadequate supply of materials, difficulties in sourcing materials across jurisdictions, and the need for unforeseen manufacturing changes.
*   Animal models for some pursued diseases may be inadequate or non-existent.

**5. Financial Implications**
*   If the company fails to develop viable product candidates, achieve regulatory approval, or successfully market and sell products, it may never achieve profitability.
*   Success is highly dependent on the development of CRISPR-based technologies, delivery methods, and therapeutic applications for specific indications. Progress in one area does not guarantee success in others.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology and Development Risks:** CRISPR genome editing technology, particularly in vivo therapies, is relatively new and its therapeutic utility is largely unproven. The approaches used to discover and develop these novel therapeutics are unproven and may never lead to marketable products. There is no assurance that the company will successfully solve issues related to safe delivery, efficacy, specificity, potency, purity, and safety.
*   **Regulatory Approval Uncertainty:** While one CRISPR-edited ex vivo therapy has been approved in the U.S. and EU, no genome editing in vivo therapy has been approved in these or other key jurisdictions. The potential to obtain approval for the company’s product candidates remains uncertain. Failure to develop viable candidates, achieve regulatory approval, or successfully market and sell products could prevent the company from achieving profitability.
*   **Public Perception and Adoption Barriers:** Public perception, media coverage of safety or efficacy issues, and ethical concerns regarding genome editing may negatively impact subject participation in clinical trials and the willingness of physicians and patients to accept treatments. Physicians and healthcare providers may be slow to adopt new technologies due to additional costs, training requirements, or perceived complexity and risk. Additionally, certain patients may not be candidates for these therapies due to health conditions or genetic profiles.
*   **Legislative and Regulatory Changes:** Responses by government agencies to negative public perception or ethical concerns may result in new legislation, regulations, or medical standards that limit the ability to develop, commercialize, or obtain regulatory approval for product candidates.
*   **Costly and Lengthy Clinical Development:** Clinical development is expensive, difficult to design, and can take many years with an uncertain outcome. There is no guarantee that programs will prove effective and safe in humans or receive regulatory approval. Preclinical and clinical data are susceptible to varying interpretations, and many companies have failed to obtain approval despite satisfactory earlier results.
*   **Clinical Trial Challenges:** The company may experience delays or failures in clinical trials, including challenges in obtaining regulatory authorization, meeting stringent requirements for later-phase trials, or establishing clinically meaningful endpoints. Interim results do not necessarily predict final results, and unforeseen events during trials could delay or prevent marketing approval.

## Pre-written sections (judge input)

### Financial Health

Intellia Therapeutics, Inc. (NTLA) currently trades at $12.75 with a market capitalization of approximately $1.79 billion. The company reported revenue of $59.5 million but incurred a net loss of nearly $400 million, resulting in a negative profit margin and a forward P/E ratio of -4.91. This significant net loss highlights the substantial cash burn typical of early-stage biotechnology firms focused on R&D and commercialization. While the stock has recovered from its 52-week low of $7.95, it remains well below its 52-week high of $28.25, reflecting ongoing investor caution regarding near-term profitability.

### Recent Developments

Intellia Therapeutics continues to navigate significant financial headwinds, evidenced by a substantial net loss of nearly $400 million in the most recent fiscal year and a negative forward P/E ratio. The company's stock has experienced considerable volatility, trading well below its 52-week high of $28.25 and currently hovering near the lower end of its annual range. Recent SEC filings highlight persistent and emerging risk factors that could materially adversely affect the company's business prospects and financial condition. Investors should remain cautious as the biotechnology firm works to stabilize its operations and demonstrate a clear path toward profitability amidst these ongoing challenges.

### SEC Filing Highlights
Intellia Therapeutics highlights significant risks associated with its unproven *in vivo* CRISPR technology, noting that no genome editing therapies of this type have yet received regulatory approval in key jurisdictions. The company faces substantial regulatory uncertainty, particularly regarding the pending resolution of a clinical hold on the MAGNITUDE trial for nexiguran ziclumeran (NTLA-2001). Operational challenges include potential delays in clinical enrollment, manufacturing supply chain constraints, and the lack of adequate animal models for certain disease indications. Furthermore, commercialization hurdles such as slow physician adoption, payer resistance, and public perception of genome editing may impede market acceptance. Consequently, the company warns that failure to navigate these developmental, regulatory, and commercial risks could prevent it from ever achieving profitability.

### Risk Factors

*   **Unproven Technology and Development Risks:** In vivo CRISPR genome editing is a novel approach with largely unproven therapeutic utility; the company faces significant challenges in ensuring safe delivery, efficacy, specificity, and potency, with no assurance that these efforts will yield marketable products.
*   **Regulatory Approval Uncertainty:** No genome editing in vivo therapy has been approved in key jurisdictions to date, creating substantial uncertainty regarding the company’s ability to obtain regulatory approval, successfully commercialize products, or achieve profitability.
*   **Public Perception and Adoption Barriers:** Ethical concerns, media coverage, and negative public perception regarding genome editing may hinder clinical trial participation and slow physician adoption, while legislative changes in response to these concerns could further restrict development and commercialization.

## Audited (Exec Summary + Outlook)

### Executive Summary
Intellia Therapeutics is a pioneering biotechnology firm focused on developing *in vivo* CRISPR genome editing therapies, currently operating with a market capitalization of approximately $1.79 billion despite reporting a substantial net loss of nearly $400 million. The stock is notable for its significant volatility and current trading position well below its 52-week high, reflecting investor caution regarding the company's path to profitability amidst heavy cash burn. The single most important near-term variable shaping the investment outcome is the regulatory resolution of the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran (NTLA-2001).

### Outlook
The directional outlook for Intellia is cautiously constructive but heavily contingent on regulatory milestones and operational execution. Key variables to monitor include the timely lifting of the clinical hold on the MAGNITUDE trial, the company’s ability to manage manufacturing supply chain constraints, and the pace of physician adoption amidst potential payer resistance. A favorable resolution to the regulatory uncertainty surrounding its *in vivo* CRISPR platform would significantly strengthen the investment thesis by validating the technology’s utility and improving the path to commercialization. Conversely, continued delays in clinical enrollment, persistent negative public perception, or further setbacks in securing regulatory approvals would weaken the view by extending the timeline to profitability and increasing cash burn risks.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "market capitalization of approximately $1.79 billion"
LABEL: SUPPORTED
REASON: The raw source data lists market_cap = 1,786,615,296.0 USD, which rounds to approximately $1.79 billion; the pre-written Financial Health section also states "approximately $1.79 billion."

---

CLAIM: "a substantial net loss of nearly $400 million"
LABEL: SUPPORTED
REASON: The raw source data lists net_income = -399,975,008.0 USD, which is nearly $400 million; the pre-written sections also confirm "net loss of nearly $400 million."

---

CLAIM: "well below its 52-week high"
LABEL: SUPPORTED
REASON: Current price is $12.75 and the 52-week high is $28.25; $12.75 is 54.9% below $28.25, confirming the stock is well below its 52-week high arithmetically.

---

CLAIM: "clinical hold on the MAGNITUDE trial for nexiguran ziclumeran (NTLA-2001)"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights section explicitly states "pending resolution of a clinical hold on the MAGNITUDE trial" for "nexiguran ziclumeran (NTLA-2001)," and the SEC Filing Highlights pre-written section repeats this verbatim.

---

**OUTLOOK**

---

CLAIM: "timely lifting of the clinical hold on the MAGNITUDE trial"
LABEL: SUPPORTED
REASON: The clinical hold on the MAGNITUDE trial is explicitly referenced in the RAG — SEC Highlights and the pre-written SEC Filing Highlights section as a key pending regulatory matter.

---

CLAIM: "manufacturing supply chain constraints"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly identifies "manufacturing and supply chain risks" and "manufacturing supply chain constraints" as a named operational challenge, and the pre-written SEC Filing Highlights section repeats this.

---

CLAIM: "pace of physician adoption amidst potential payer resistance"
LABEL: SUPPORTED
REASON: Both the RAG — SEC Highlights and the pre-written Risk Factors and SEC Filing Highlights sections explicitly name slow physician adoption and payer resistance as commercialization hurdles.

---

CLAIM: "continued delays in clinical enrollment"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and RAG — Risk Factors both explicitly identify potential delays in clinical enrollment as a named risk factor.

---

CLAIM: "persistent negative public perception"
LABEL: SUPPORTED
REASON: Public perception and ethical concerns regarding genome editing are explicitly named as risk factors in both RAG sections and the pre-written Risk Factors section.

---

CLAIM: "further setbacks in securing regulatory approvals"
LABEL: SUPPORTED
REASON: Regulatory approval uncertainty is explicitly and repeatedly named as a primary risk factor across all source sections.

---

CLAIM: "extending the timeline to profitability and increasing cash burn risks"
LABEL: INFERENCE
REASON: No specific timeline-to-profitability figure or cash burn rate is stated in the source data; however, this is a direct logical inference from the source's explicit statements that failure to obtain approvals "could prevent the company from ever achieving profitability" and the documented ~$400 million annual net loss indicating ongoing cash burn.

---

**SUMMARY NOTE:** The Executive Summary and Outlook contain no specific numerical price targets, explicit percentage figures, ratio values, or period-labeled financial metrics beyond those already evaluated above. All quantitative and forward-looking claims are either directly supported by the source data or, in one case, a clearly labeled inference from present facts.
